Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review.

Abstract:

:Ghrelin is a hormone with multiple physiologic functions, including promotion of growth hormone release, stimulation of appetite and regulation of energy homeostasis. Treatment with ghrelin/ghrelin-receptor agonists is a prospective therapy for disease-related cachexia and malnutrition. In vitro studies have shown high expression of ghrelin in cancer tissue, although its role including its impact in cancer risk and progression has not been established. We performed a systematic literature review to identify peer-reviewed human or animal in vivo original research studies of ghrelin, ghrelin-receptor agonists, or ghrelin genetic variants and the risk, presence, or growth of cancer using structured searches in PubMed database as well as secondary searches of article reference lists, additional reviews and meta-analyses. Overall, 45 (73.8%) of the 61 studies reviewed, including all 11 involving exogenous ghrelin/ghrelin-receptor agonist treatment, reported either a null (no statistically significant difference) or inverse association of ghrelin/ghrelin-receptor agonists or ghrelin genetic variants with cancer risk, presence or growth; 10 (16.7%) studies reported positive associations; and 6 (10.0%) reported both negative or null and positive associations. Differences in serum ghrelin levels in cancer cases vs controls (typically lower) were reported for some but not all cancers. The majority of in vivo studies showed a null or inverse association of ghrelin with risk and progression of most cancers, suggesting that ghrelin/ghrelin-receptor agonist treatment may have a favorable safety profile to use for cancer cachexia. Additional large-scale prospective clinical trials as well as basic bioscientific research are warranted to further evaluate the safety and benefits of ghrelin treatment in patients with cancer.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Sever S,White DL,Garcia JM

doi

10.1530/ERC-16-0130

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

R393-409

issue

9

eissn

1351-0088

issn

1479-6821

pii

23/9/R393

journal_volume

23

pub_type

杂志文章,评审
  • Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

    abstract::Prostate cancer development and progression is largely dependent on androgen receptor (AR) signaling. AR is a hormone-dependent transcription factor, which binds to thousands of sites throughout the human genome to regulate expression of directly responsive genes, including pro-survival genes that enable tumor cells t...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0181

    authors: Stelloo S,Linder S,Nevedomskaya E,Valle-Encinas E,de Rink I,Wessels LFA,van der Poel H,Bergman AM,Zwart W

    更新日期:2020-02-01 00:00:00

  • The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.

    abstract::Breast and prostate cancer are the most well-characterized cancers of the type that have their development and growth controlled by the endocrine system. These cancers are the leading causes of cancer death in women and men, respectively, in the United States. Being hormone-dependent tumors, antihormone therapies usua...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01026

    authors: Rau KM,Kang HY,Cha TL,Miller SA,Hung MC

    更新日期:2005-09-01 00:00:00

  • p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer.

    abstract::Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time chemotherapy resistance emerges and there is urgent need to find new therapeutic targets to ov...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0488

    authors: Gruber M,Ferrone L,Puhr M,Santer FR,Furlan T,Eder IE,Sampson N,Schäfer G,Handle F,Culig Z

    更新日期:2020-03-01 00:00:00

  • HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs.

    abstract::The 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) held in Houston, TX, USA, focused on emerging topics in the pathogenesis and therapy of malignant endocrine tumors associated with MEN syndromes. With MEN-2 syndromes, the most common malignancy is medullary thyroid carcinoma (MTC). In the spirit o...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0110

    authors: Dadu R,Bagheri-Yarmand R,Ringel MD,Grubbs EG,Zafereo M,Cote G,Gagel RF,Robinson BG,Shaw KR,Hu MI

    更新日期:2020-08-01 00:00:00

  • PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A.

    abstract::Genetic variants in components of the protein kinase A (PKA) enzyme have been associated with various defects and neoplasms in the context of Carney complex (CNC) and in isolated cases, such as in primary pigmented nodular adrenocortical disease (PPNAD), cortisol-producing adrenal adenomas (CPAs), and various cancers....

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0309

    authors: Espiard S,Drougat L,Settas N,Haydar S,Bathon K,London E,Levy I,Faucz FR,Calebiro D,Bertherat J,Li D,Levine MA,Stratakis CA

    更新日期:2020-11-01 00:00:00

  • Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.

    abstract::Pheochromocytomas are catecholamine-producing tumors which are generally benign, but which can also present as or develop into malignancy. Molecular pathways of malignant transformation remain poorly understood. Pheochromocytomas express various trophic peptides which may influence tumoral cell behavior. Here, we inve...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-10-0109

    authors: Thouënnon E,Pierre A,Tanguy Y,Guillemot J,Manecka DL,Guérin M,Ouafik L,Muresan M,Klein M,Bertherat J,Lefebvre H,Plouin PF,Yon L,Anouar Y

    更新日期:2010-06-25 00:00:00

  • CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.

    abstract::Pancreatic neuroendocrine neoplasms (PNENs) constitute a rare tumour entity, and prognosis and treatment options depend on tumour-mediating hallmarks such as angiogenesis, proliferation rate and resistance to apoptosis. The molecular pathways that determine the malignant phenotype are still insufficiently understood a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0152

    authors: Krug S,Kühnemuth B,Griesmann H,Neesse A,Mühlberg L,Boch M,Kortenhaus J,Fendrich V,Wiese D,Sipos B,Friemel J,Gress TM,Michl P

    更新日期:2014-01-01 00:00:00

  • Uncontrolled insulin secretion from a childhood pancreatic beta-cell adenoma is not due to the functional loss of ATP-sensitive potassium channels.

    abstract::We report the case of an 8-year-old child who presented with severe hyperinsulinaemic hypoglycaemia due to a pancreatic islet cell adenoma. In vivo, there was no beneficial response to the hyperglycaemia-inducing agent diazoxide and as a consequence the child underwent a subtotal pancreatectomy. In vitro studies of ad...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.0.0090221

    authors: Hussain K,Cosgrove KE,Shepherd RM,Chapman JC,Swift SM,Smith VV,Kassem SA,Glaser B,Lindley KJ,Aynsley-Green A,Dunne MJ

    更新日期:2002-12-01 00:00:00

  • Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF.

    abstract::Pituitary tumor-transforming gene 1-binding factor (PTTG1IP; PBF) is a multifunctional glycoprotein, which is overexpressed in a wide range of tumours, and significantly associated with poorer oncological outcomes, such as early tumour recurrence, distant metastasis, extramural vascular invasion and decreased disease-...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0340

    authors: Imruetaicharoenchoke W,Fletcher A,Lu W,Watkins RJ,Modasia B,Poole VL,Nieto HR,Thompson RJ,Boelaert K,Read ML,Smith VE,McCabe CJ

    更新日期:2017-09-01 00:00:00

  • MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.

    abstract::Type 3 deiodinase (DIO3, D3) is reactivated in human neoplasias. Increased D3 levels in papillary thyroid carcinoma (PTC) have been associated with tumor size and metastatic disease. The objective of this study is to investigate the signaling pathways involved in DIO3 upregulation in PTC. Experiments were performed in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0162

    authors: Romitti M,Wajner SM,Ceolin L,Ferreira CV,Ribeiro RV,Rohenkohl HC,Weber Sde S,Lopez PL,Fuziwara CS,Kimura ET,Maia AL

    更新日期:2016-03-01 00:00:00

  • The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.

    abstract::Long-term culture of MCF-7 wild-type (wt) cells in steroid-depleted medium (LTED) results in hypersensitivity to oestradiol (E2) coinciding with elevated levels of ERalpha and enhanced growth factor signalling. In this study, we aimed to compare the effects of the pure anti-oestrogen ICI 182,780 (ICI) with the competi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.00905

    authors: Martin LA,Pancholi S,Chan CM,Farmer I,Kimberley C,Dowsett M,Johnston SR

    更新日期:2005-12-01 00:00:00

  • Tetrac as an anti-angiogenic agent in cancer.

    abstract::The thyroid hormones T3 and T4 have emerged as pro-angiogenic hormones with important implications for cancer management. Endogenous circulating hormone levels may help stimulate cancer progression and limit the effectiveness of anticancer therapy, though clinical data remain inconclusive. The capacity of thyroid horm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0058

    authors: Schmohl KA,Nelson PJ,Spitzweg C

    更新日期:2019-06-01 00:00:00

  • The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.

    abstract::Imatinib mesylate (IM), a small molecule that is a selective inhibitor of the ABL, platelet derived growth factor receptor (PDGFR-R) and stem cell ligand receptor (c-kit) tyrosine kinases (TK). IM was also found to inhibit the TK activity of BCR/ABL fusion protein produced in chronic myelogenous leukemia, with marked ...

    journal_title:Endocrine-related cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1677/erc.1.01124

    authors: Gross DJ,Munter G,Bitan M,Siegal T,Gabizon A,Weitzen R,Merimsky O,Ackerstein A,Salmon A,Sella A,Slavin S,Israel Glivec in Solid Tumors Study Group.

    更新日期:2006-06-01 00:00:00

  • Using genetics to inform the pharmacological targeting of neuroendocrine neoplasms.

    abstract::Neuroendocrine neoplasms (NEN) are a class of tumours heterogeneous in terms of their anatomical sites of origin and clinical behaviour. Outdated perspectives of indolence have been superseded by appreciation for their myriad clinical challenges, such as the high rates of regional and distant metastases at initial dia...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-20-0074

    authors: Clift AK,Frilling A

    更新日期:2020-09-01 00:00:00

  • lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling.

    abstract::Pancreatic neuroendocrine neoplasms (pNENs) are endocrine tumors arising in pancreas and is the most common neuroendocrine tumors. Mounting evidence indicates lncRNA H19 could be a determinant of tumor progression. However, the expression and mechanism of H19 and the relevant genes mediated by H19 in pNENs remain unde...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0552

    authors: Ji M,Yao Y,Liu A,Shi L,Chen D,Tang L,Yang G,Liang X,Peng J,Shao C

    更新日期:2019-07-01 00:00:00

  • Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment.

    abstract::Because intracellular polyamines have a critical role in cell proliferation and death pathways, the polyamine metabolic pathway represents a potential target for intervention in cancers. A number of polyamine analogues have been identified that downregulate polyamine synthesis and enhance polyamine catabolism, thereby...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060069

    authors: Davidson NE,Hahm HA,McCloskey DE,Woster PM,Casero RA Jr

    更新日期:1999-03-01 00:00:00

  • Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases.

    abstract::Cholesterol and sex steroid hormones including androgens and estrogens play a critical role in the development and progression of urological diseases such as prostate cancer. This disease remains the most commonly diagnosed malignant tumor in men and is the leading cause of death from different cancers. Attempts to un...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0285

    authors: Moon JY,Choi MH,Kim J

    更新日期:2016-10-01 00:00:00

  • Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.

    abstract::There are currently few successful therapies for castration-resistant prostate cancer (CRPC). CRPC is thought to result from augmented activation of the androgen/androgen receptor (AR) signaling pathway, which could be enhanced by AR cofactors. In this study, heterochromatin protein 1beta (HP1beta), but not HP1alpha o...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0321

    authors: Shiota M,Song Y,Yokomizo A,Tada Y,Kuroiwa K,Eto M,Oda Y,Inokuchi J,Uchiumi T,Fujimoto N,Seki N,Naito S

    更新日期:2010-05-18 00:00:00

  • Management of carcinoid syndrome: a systematic review and meta-analysis.

    abstract::Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine tumors. Several treatment options are available to alleviate the hormonal symptoms, but their relative efficacy is unknown. Online databases were searched for publications on the treatment of CS symptoms. Independent reviewers assess...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,meta分析

    doi:10.1530/ERC-18-0495

    authors: Hofland J,Herrera-Martínez AD,Zandee WT,de Herder WW

    更新日期:2019-03-01 00:00:00

  • 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

    abstract::177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncomm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0509

    authors: Hofving T,Sandblom V,Arvidsson Y,Shubbar E,Altiparmak G,Swanpalmer J,Almobarak B,Elf AK,Johanson V,Elias E,Kristiansson E,Forssell-Aronsson E,Nilsson O

    更新日期:2019-04-01 00:00:00

  • HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Early thyroidectomy in multiple endocrine neoplasia: a four decade experience.

    abstract::Forty years ago, physicians caring for the J-kindred, a 100+ member family with multiple endocrine neoplasia type 2A (MEN2A), hypothesized that early thyroidectomy based on measurement of the biomarker calcitonin could cure patients at risk for development of medullary thyroid carcinoma (MTC). We re-evaluated 22 famil...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0108

    authors: Grubbs EG,Lechan RM,Edeiken-Monroe B,Cote GJ,Trotter C,Tischler AS,Gagel RF

    更新日期:2020-08-01 00:00:00

  • Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells.

    abstract::The expression of estrogen receptor α (ERα) in breast cancer identifies patients most likely to respond to endocrine treatment. The second ER, ERβ, is also expressed in breast tumors, but its function and therapeutic potential need further study. Although in vitro studies have established that ERβ opposes transcriptio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0444

    authors: Jonsson P,Katchy A,Williams C

    更新日期:2014-01-30 00:00:00

  • Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.

    abstract::Therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) are limited due to lack of effective treatments. Thus, there is a need to thoroughly characterize the pathways of molecular pathogenesis and to identify potential targets for therapy in MTC. Since epidermal growth factor receptor (EGFR)...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0304

    authors: Rodríguez-Antona C,Pallares J,Montero-Conde C,Inglada-Pérez L,Castelblanco E,Landa I,Leskelä S,Leandro-García LJ,López-Jiménez E,Letón R,Cascón A,Lerma E,Martin MC,Carralero MC,Mauricio D,Cigudosa JC,Matias-Guiu X,Roble

    更新日期:2010-01-29 00:00:00

  • Enriched environment inhibits breast cancer progression in obese models with intact leptin signaling.

    abstract::Obesity is becoming a global epidemic and is a risk factor for breast cancer. Environmental enrichment (EE), a model recapitulating an active lifestyle, leads to leanness, resistance to diet-induced obesity (DIO) and cancer. One mechanism is the activation of the hypothalamic-sympathoneural-adipocyte (HSA) axis. This ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0075

    authors: Foglesong GD,Queen NJ,Huang W,Widstrom KJ,Cao L

    更新日期:2019-05-01 00:00:00

  • Autophagy in endocrine tumors.

    abstract::Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a 'double-edged sword,' a term that reflects its known participation in tumor suppress...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0042

    authors: Weckman A,Rotondo F,Di Ieva A,Syro LV,Butz H,Cusimano MD,Kovacs K

    更新日期:2015-08-01 00:00:00

  • IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

    abstract::Epidemiologic and experimental evidence suggest that a subset of breast cancer is insulin responsive, but it is unclear whether safe and effective therapies that target the insulin receptor (IR), which is homologous to oncogenes of the tyrosine kinase class, can be developed. We demonstrate that both pharmacologic inh...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0136

    authors: Dool CJ,Mashhedi H,Zakikhani M,David S,Zhao Y,Birman E,Carboni JM,Gottardis M,Blouin MJ,Pollak M

    更新日期:2011-11-14 00:00:00

  • Autophagy and thyroid carcinogenesis: genetic and epigenetic links.

    abstract::Thyroid cancer is the most common cancer of the endocrine system and is responsible for the majority of deaths from endocrine malignancies. Although a large proportion of thyroid cancers belong to well differentiated histologic subtypes, which in general show a good prognosis after surgery and radioiodine ablation, th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-13-0271

    authors: Morani F,Titone R,Pagano L,Galetto A,Alabiso O,Aimaretti G,Isidoro C

    更新日期:2013-12-16 00:00:00

  • Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma.

    abstract::Ten to fifteen percent of fine-needle aspiration biopsy (FNAB) of thyroid nodules are indeterminate. Galectin-3 (Gal-3) and the oncogene BRAFV600E are markers of malignancy useful to improve FNAB accuracy. The objective of this study was to determine whether the combined analysis of Gal-3 and BRAFV600E expression in t...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-07-0147

    authors: Sapio MR,Guerra A,Posca D,Limone PP,Deandrea M,Motta M,Troncone G,Caleo A,Vallefuoco P,Rossi G,Fenzi G,Vitale M

    更新日期:2007-12-01 00:00:00

  • Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes.

    abstract::Evidence supports a role of 17&-estradiol (E2) in carcinogenesis and the large majority of breast carcinomas are dependent on estrogen. The anti-estrogen tamoxifen (TAM) is widely used for both treatment and prevention of breast cancer; however, it is also carcinogenic in human uterus and rat liver, highlighting the p...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0078

    authors: Rondón-Lagos M,Rangel N,Di Cantogno LV,Annaratone L,Castellano I,Russo R,Manetta T,Marchiò C,Sapino A

    更新日期:2016-08-01 00:00:00

  • SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.

    abstract::Thyroid cancer is on the rise. Novel approaches are needed to improve the outcome of patients with recurrent and advanced metastatic thyroid cancers. FDA approval of suberoylanilide hydroxamic acid (SAHA; vorinostat), an inhibitor of histone deacetylase, for the treatment of hematological malignancies led to the clini...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0103

    authors: Zhu X,Kim DW,Zhao L,Willingham MC,Cheng SY

    更新日期:2016-07-01 00:00:00